Atai Life Sciences N.V. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ATAI Nasdaq 2830 www.atai.life

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Atai Life Sciences N.V.

Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Jan 13th, 2025 12:58 am
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health - Jan 10th, 2025 12:00 pm
US Penny Stocks To Consider In December 2024 - Dec 30th, 2024 1:12 pm
Oxbridge Re Holdings Among 3 US Penny Stocks To Watch - Nov 19th, 2024 1:04 pm
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - Nov 13th, 2024 1:00 pm
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer - Nov 11th, 2024 12:30 pm
374Water And 2 Other Promising US Penny Stocks To Watch - Oct 21st, 2024 7:07 pm
atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit - Oct 15th, 2024 12:00 pm
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Sep 4th, 2024 11:00 am
atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - Aug 13th, 2024 11:10 am
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT) - Aug 13th, 2024 11:00 am
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference - Aug 7th, 2024 11:00 am
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference - Jun 26th, 2024 11:00 am
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a - Jun 20th, 2024 11:00 am
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference - May 31st, 2024 11:00 am
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors - May 23rd, 2024 11:00 am
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates - May 15th, 2024 10:59 am
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression - Apr 24th, 2024 11:00 am
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology - Apr 17th, 2024 11:00 am
Atai Life Sciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag - Apr 1st, 2024 7:00 pm